VRDN
Viridian Therapeutics, Inc.\DE
NASDAQ · Healthcare · Biotechnology · US
$28.74
+14.25%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$1.02
- Revenue estimate
- $4.7M
Latest reported
- Last report date
- Nov 4, 2026
- EPS actual
- -$0.81
- EPS estimate
- -$1.02
- Revenue actual
- $25.8M
- Revenue estimate
- $4.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +23.1%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $39
- PT range
- $38 – $39
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 4, 2026 | -$1.02 | -$0.81 | Beat 20.59% | $25.8M |
| Aug 6, 2026 | -$1.03 | -$1.05 | Miss -1.94% | $284.0K |
| May 5, 2026 | -$1.06 | -$0.90 | Beat 15.09% | $141.0K |
| Nov 5, 2025 | -$0.82 | -$0.34 | Beat 58.54% | $70.6M |
| Feb 27, 2025 | -$1.05 | -$0.81 | Beat 22.86% | $72.0K |
| Aug 8, 2024 | -$0.89 | -$1.02 | Miss -14.61% | $72.0K |
| Feb 27, 2024 | -$1.00 | -$1.35 | Miss -35.00% | $72.0K |
| Nov 13, 2023 | -$1.27 | -$1.09 | Beat 14.17% | $72.0K |
| Mar 8, 2023 | -$0.73 | -$1.13 | Miss -54.79% | $105.0K |
| Nov 14, 2022 | -$1.02 | -$0.86 | Beat 15.69% | $1.2M |
| Aug 15, 2022 | -$0.90 | -$1.06 | Miss -17.78% | $256.0K |
| May 12, 2022 | -$1.08 | -$0.98 | Beat 9.26% | $216.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 25, 2027